Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
3(38%)
Results Posted
40%(2 trials)

Phase Distribution

Ph not_applicable
1
13%
Ph phase_1
2
25%
Ph phase_4
1
13%
Ph phase_3
2
25%
Ph phase_2
1
13%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(5)

Detailed Status

Completed5
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 21 (14.3%)
Phase 32 (28.6%)
Phase 41 (14.3%)
N/A1 (14.3%)

Trials by Status

active_not_recruiting338%
completed563%

Recent Activity

3 active trials
Showing 5 of 8
active_not_recruitingphase_3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311
active_not_recruitingphase_3

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808
active_not_recruitingphase_2

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341
completednot_applicable

Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN

NCT06629480
completed

Gut Microbiota, PGx and INSTIs Response

NCT04805944
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05979311Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

Active Not Recruiting
NCT06333808Phase 3

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Active Not Recruiting
NCT05502341Phase 2

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Active Not Recruiting
NCT06629480Not Applicable

Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN

Completed
NCT04805944

Gut Microbiota, PGx and INSTIs Response

Completed
NCT03499483Phase 4

Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

Completed
NCT02275065Phase 1

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

Completed
NCT02400307Phase 1

Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8